A Study of RO5185426 (PLX4032) in Previously Treated Patients With Metastatic Melanoma
GPTKB entity
Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.govIdentifier |
NCT00949702
|
| gptkbp:conditionStudied |
metastatic melanoma
|
| gptkbp:enrollment |
132
|
| https://www.w3.org/2000/01/rdf-schema#label |
A Study of RO5185426 (PLX4032) in Previously Treated Patients With Metastatic Melanoma
|
| gptkbp:intervention |
gptkb:drug
|
| gptkbp:location |
gptkb:Australia
gptkb:Europe gptkb:United_States |
| gptkbp:patientPopulation |
previously treated patients
|
| gptkbp:period |
Phase II
|
| gptkbp:result |
overall response rate
|
| gptkbp:sponsor |
gptkb:Hoffmann-La_Roche
|
| gptkbp:startDate |
2010
|
| gptkbp:studiesDrug |
gptkb:PLX4032
gptkb:RO5185426 |
| gptkbp:bfsParent |
gptkb:NCT01327846
|
| gptkbp:bfsLayer |
7
|